New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
07:17 EDTRPTPRaptor Pharmaceuticals initiated with a Buy at Janney Capital
Target $9.
News For RPTP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2015
17:19 EDTRPTPRaptor Pharmaceuticals' expanded label for Procysbi approved by FDA
Subscribe for More Information
August 17, 2015
07:07 EDTRPTPRaptor Pharmaceuticals receives FDA approval of expanded label for Procysbi
Raptor Pharmaceutical announced that the FDA approved the expanded use of Procysbi delayed-release capsules to treat children two to six years of age with nephropathic cystinosis. The approved supplement was based on efficacy and safety data from an ongoing long-term extension study in which a cohort of children aged 2 to 6 years were enrolled and treated with Procysbi for 12 months. Additionally, data submitted as part of this supplement supported the long-term maintenance of white blood cell cystine levels and renal function in all age groups studied during extended treatment with Procysbi. Procysbi is now approved for the treatment of nephropathic cystinosis in adult and in pediatric patients 2 years of age and older in the U.S.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use